FDA okays start of BrainStorm stem cell trial in ALS patients

Date Posted: Sunday, April 27, 2014

The U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of BrainStorm Cell Therapeutics’ adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS).  The Phase 2 trial will be launched initially at the University of Massachusetts Medical School.
Market Watch
MedCity News

▴ Back To Top
Section Menu To Top